We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.79 | -0.62% | 127.47 | 128.48 | 127.18 | 128.11 | 6,221,929 | 01:00:00 |
From May 2019 to May 2024
By Colin Kellaher
Merck & Co. (MRK) on Wednesday said the Food and Drug Administration accepted and granted priority review for a new supplemental Biologics License Application seeking approval for Keytruda in advanced liver cancer.
The Kenilworth, N.J., drug maker said the sBLA seeks accelerated approval for Keytruda as a treatment for previously treated patients with advanced hepatocellular carcinoma. The FDA has set a target action date of Nov. 9, Merck said.
Hepatocellular carcinoma is the most common type of liver cancer in adults, Merck said. An estimated 42,200 new cases of liver cancer will be diagnosed in the U.S. this year.
Keytruda, a new type of cancer drug that harnesses patients' immune systems to fight tumors, is already marketed to treat lung, skin, bladder and other cancers.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
July 11, 2018 07:32 ET (11:32 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
